Inhaled medicines for the treatment of viral and fungal infections of the respiratory tract
Pulmocide has raised €28M across 1 funding round from 6 investors, most recently a Series B round in Mar 2017. Based in London, UK; founded 2013; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2017-03-01 | Series B |
| €28M |
| F Prime Capital,Johnson & Johnson,Johnson & Johnson Innovation,SR One,SV Life Sciences,Touchstone Innovations |
| View deal → |
